Patent Number: 6,309,816

Title: Methods for diagnosing cancer by measuring creatine kinase

Abstract: The diagnostic method of the present invention provides a method of diagnosing prostate cancer by measuring the concentration of prostate specific antigen and creatine kinase enzyme activity. A mathematical relationship between the two concentrations is then determined. If the prostate specific antigen concentration in the blood is normal or near normal and the creatine kinase enzyme value is lower than normal, than there is a high likelihood that the patient has prostate cancer. The present invention also includes the measurement of creatine kinase enzyme inhibitor in the serum of a patient to determine if the patient has a high likelihood of cancer.

Inventors: Zhang; Zhen (Mt. Pleasant, SC), Barnhill; Stephen D. (Savannah, GA), Madyastha; Ramananda (Charleston, SC), Zhang; Hong (Savannah, GA)

Assignee: Horus Therapeutics, Inc.

International Classification: G01N 33/574 (20060101); C12Q 001/00 (); G01N 033/53 (); G01N 033/573 ()

Expiration Date: 10/30/2018